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Abstract: Cushing’s disease, due to pituitary adrenocorticotropic hormone (ACTH) 
hypersecretion, is the most common etiology of spontaneous excess cortisol production. The 
majority of pituitary tumors causing Cushing’s disease measure 1 cm and the excess morbidity 
associated with these tumors is mostly due to the effects of elevated, nonsuppressible, ACTH 
levels leading to adrenal steroid hypersecretion. Elevated circulating cortisol levels lead to 
abnormal fat deposition, hypertension, diabetes, coronary artery disease, osteoporosis, muscle 
weakness and psychological disturbances. At experienced centers, initial surgical remission 
rate via transnasal, transphenoidal resection approaches 80% for tumors less than 1 cm, but 
may be as low as 30% for larger lesions and long-term recurrence in all groups approaches 
25%. Residual disease may be managed with more radical surgery, pituitary-directed radiation, 
bilateral adrenalectomy, or medical therapy. This paper addresses current and novel therapies 
in various stages of development for Cushing’s disease.
Keywords: Cushing’s disease, treatment, pasireotide, PPAR-γ, 11 β-hydroxysteroid 
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Background
Pituitary tumors account for approximately 15% of intracranial tumors and are 
associated with significant morbidity due to both local compressive effects and 
hormonal hypersecretion. These tumors are classified based on their hormonal activity 
and cytologic origin. Pituitary tumors may produce hormones (approximately 2/3) 
including prolactin (PRL) in prolactinomas, adrenocorticotropic hormone (ACTH) 
in Cushing’s disease, growth hormone (GH) in acromegaly, thyroid-stimulating 
hormone (TSH) in thyrotropinomas, or infrequently, the gonadotropins (luteinizing 
hormone [LH] and/or follicle-stimulating hormone [FSH]) in gonadotropinomas. 
Hormonally active tumors are typically diagnosed because of symptoms of hormone 
excess, such as menstrual irregularity, galactorrhea, and/or infertility in the case 
of PRL-secreting tumors. Silent tumors, on the other hand typically present when 
compressive symptoms, including vision loss, headache, or hypopituitarism 
develop.
Cushing’s disease, due to pituitary ACTH hypersecretion, is the most common 
etiology of spontaneous excess cortisol production.1 These ACTH-secreting anterior 
pituitary tumors are usually benign adenomas with 90% measuring less than 1 cm. 
In fact, 50% of identified tumors are less than 5 mm and large invasive tumors are 
quite rare.International Journal of General Medicine 2009:2 210
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Corticotroph cells account for 10%–20% of normal 
anterior pituitary cells and secrete ACTH in response 
to hypothalamic-derived corticotrophic-releasing hor-
mone (CRH) and are inhibited by adrenal-derived 
glucocorticoids. ACTH-secreting tumors largely function 
independently of CRH or cortisol, and this disruption 
of normal feedback loops in the hypothalamic–pituitary 
axis (HPA) results in loss of circadian rhythm and excess 
cortisol production.
The onset of symptoms associated with elevated ACTH 
levels and adrenal steroid hypersecretion is typically 
insidious with many disabling signs and symptoms. These 
include obesity with predominantly central fat distribution, 
thinning of the skin, hypertension, glucose intolerance and 
gonadal dysfunction. Muscle weakness, osteoporosis, easy 
bruisability, hirsutism, and psychiatric disturbances are also 
common. Without appropriate treatment, this condition is 
associated with increased morbidity and mortality, largely 
due to increased cerebrovascular and cardiovascular 
disease, including coronary artery disease and congestive 
heart failure. Cortisol excess is known to induce vascular 
disease both directly, causing premature atherosclerosis, 
and indirectly, via the development of obesity, hypertension, 
dyslipidemia, and impaired glucose tolerance.2,3
Therapy for pituitary tumors is determined based on the 
type of tumor and presence or absence of hormonal activity. 
For example, in PRL- and GH-secreting tumors, medications 
such as dopamine agonists or somatostatin analogs have been 
shown to suppress hormone secretion and control tumor 
growth, in 80%–90% of patients treated with dopamine 
agonists4 and in 75%–80% of patients treated with soma-
tostatin analogues.5 There are no similarly effective drug 
therapies for ACTH-producing tumors. As a result, the initial 
step in therapy for patients with corticotroph pituitary tumors 
is typically surgery to remove the lesion. At experienced 
centers, initial surgical remission rates approach 70%–80% 
via transnasal, transphenoidal resection for tumors less 
than 1 cm6 and 50% for tumors larger than 1 cm.7 However, 
recurrence rates for patients previously in remission, 
approach 20% with long-term follow-up8 and surgical cure 
rates for larger lesions may be as low as 30%.9 Therefore, in 
a significant number of patients, other treatment modalities 
must be considered.
Residual disease may require more radical surgery, such 
as hemihypophysectomy, treatment with pituitary-directed 
radiation, bilateral adrenalectomy or medical therapy. 
Radiation therapy, including external beam radiotherapy and 
stereotactic radiotherapy, is associated with risk of partial 
or total hypopituitarism in up to 50% of patients, which 
typically manifests one to two years post-therapy but may be 
delayed for up to 25 years after treatment. Additional risks 
include increased secondary tumor rates and cerebrovascular 
disease, albeit at low levels, less than one percent. Remission 
rates approach 55%–70% at 3–5 years after conventional 
radiotherapy treatment while stereotactic approaches such 
as gamma knife radiosurgery offer improved remission 
of 65%–75%. However, a significant drawback of these 
approaches is that therapy will not normalize biochemical 
disease activity for at least six to 12 months.10 An alternative 
therapeutic strategy is bilateral adrenalectomy which 
promptly resolves the patient’s hypercortisolism although 
the pituitary tumor may continue to grow, leading to the 
development of Nelson’s syndrome. The pathogenesis of 
Nelson’s syndrome is uncertain, but may be due to the 
accelerated growth of remaining ACTH-secreting cells in 
the absence of glucocorticoid-mediated negative feedback. 
In addition, bilateral adrenalectomy necessitates lifelong 
gluco- and mineralocorticoid replacement for the patient. 
Noticeably lacking at the present time is a safe, efficacious 
medical therapy for Cushing’s disease. Several compounds 
currently under investigation appear promising in their ability 
to control cortisol excess, but they do not all impact pituitary 
tumor growth.
This review will focus on novel medical therapies 
at various stages of development, including SOM230 
(pasireotide), combination D2-agonist with SMS ligands, 
retinoic acid, peroxisome proliferator-activated receptor-γ 
(PPAR-γ) ligands and 11 β-hydroxysteroid inhibitors.
Current medical therapy 
for Cushing’s disease
Successful treatment of Cushing’s disease is defined by 
normalization of plasma ACTH and cortisol levels (both in 
the serum and urine), preservation of normal anterior pitu-
itary function as well as tumor shrinkage or ablation. If these 
goals are not attained surgically, further therapy should be 
considered in the form of pituitary-directed radiation, medical 
therapy or bilateral adrenalectomy.
Given the limitations and potentially destructive effects 
of extended surgery and radiation therapy, as described 
above, drug-based therapies, at the present time, are 
reserved for patients unfit for pituitary surgery or for those 
patients who need pre-operative management of severe 
hypercortisolism. Currently available drugs primarily 
inhibit adrenal cortisol production and are mostly employed 
for pre-operative treatment of severe hypercortisolism or International Journal of General Medicine 2009:2 211
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when definitive treatment is delayed for example, due to 
intercurrent illness.
Review of existing therapies
1.  Inhibitors of adrenal steroidogenesis via inhibition 
of cytochrome P450 function. A high prevalence of 
gastrointestinal (GI) side effects limit their utility and 
ultimately, they increase ACTH levels which may in 
turn, overcome the enzyme inhibition that limits cortisol 
production.
a.  Ketoconazole has been found to inhibit multiple P450 
enzymes, including 17,20-lyase, 11 β-hydroxylase, 
17 α-hydroxylase. At doses of 600–1200 mg per 
day, either used alone or at higher doses with 
steroids (typically dexamethasone 0.5 mg BID) this 
medication has been effective in controlling cortisol 
levels. Ketoconazole remains the most common 
drug for the medical treatment of Cushing’s disease. 
Side effects include gynecomastia (13% of males), 
GI upset (8%), edema (6%), rash (2%), and elevated 
transaminases (15%). Transaminitis, when it happens, 
occurs within 60 days of the initiation of treatment. 
The hepatotoxicity typically resolves after cessation 
of therapy and severe hepatic injury is rare (1/15,000). 
Despite the ability to control excessive glucocorticoid 
secretion in some patients, a degree of escape from 
steroid suppression is typical and no inhibition of 
corticotroph tumor growth occurs.
b.  Metyrapone works by inhibiting P450c11. As a single 
therapy (250–750 mg TID), normalization of plasma 
cortisol levels occurs in up to 75% of patients. Like 
other agents in this class, dose-dependent side-effects 
often limit its clinical utility. These side effects include 
skin rash (4%), dizziness and ataxia (15%), nausea 
(5%), edema (8%), hypokalemia and worsening 
of acne or hirsutism in 70% of treated women due 
to its inhibition of aldosterone biosynthesis and 
accumulation of aldosterone precursors with weak 
mineralocorticoid activity. Of note, metyrapone is not 
commercially available in the United States, but may 
be obtained from the manufacturer (Novartis, Basel, 
Switzerland) for compassionate use.
c.  Aminoglutethimide works similarly to metyrapone by 
inhibiting P450 enzymes. Unfortunately, this medica-
tion is no longer available worldwide.
d.  Mitotane (500–3000 mg TID) is an adrenolytic 
medication which causes atrophy of the zona 
fasciculata and reticularis. While remission is 
achieved in almost 80% of patients, relapse is common 
with cessation of the medication. Additionally, a delay 
in response of weeks to months is typically seen. 
This delay, in conjunction with frequent side-effects 
including severe nausea, vomiting, diarrhea, rash and 
somnolence make long-term treatment with Mitotane 
difficult and it is mostly used for patients with hyper-
cortisolism due to adrenocortical cancer.
e.  Etomidate, an anesthetic agent (0.04–0.05 mg/kg/hour), 
is ideal in patients unable to tolerate oral medications. 
It works by inhibiting 11 β-hydroxylase and the 
cholesterol side-chain cleavage complex. At higher 
doses (0.3 mg/kg/hour), use may be limited by 
sedation and parenteral administration restricts 
long-term use.11
2.  Receptor modulators block the effects of cortisol at the 
receptor level without decreasing cortisol levels. In this 
class, only mifepristone is clinically available.
a.  Mifepristone (RU-486) is a competitive gluco-
corticoid, androgen, and progesterone receptor 
antagonist, blocking negative feedback at the hypo-
thalamic–pituitary level. Mifepristone (typical dose 
6–25 mg/kg/day) antagonizes the hypercortisolemic 
effects at the receptor level, thereby not altering 
plasma ACTH and serum cortisol levels and may 
actually cause levels to increase.12 Case reports 
document the use of mifespristone in patients with 
refractory Cushing’s disease.13 While mifepristone 
may be effective in antagonizing the effects of 
hypercortisolism, patients often develop hypokale-
mia, associated with the mineralocorticoid activity 
of cortisol excess, necessitating spironolactone. 
Reversible heart failure has also been reported due 
to sodium and fluid retention. A retrospective study 
examined 20 patients with hypercortisolism, includ-
ing four patients with Cushing’s disease treated 
with mifepristone with median starting dose of 
600 mg/day (300–600 mg/day) and median maximal 
dose of 700 mg/day (600–1200 mg/day).14 While the 
clinical signs of hypercortisolism improved rapidly 
in three of four patients (75%), two patients devel-
oped severe hypokalemia and one patient developed 
hypertension. In addition, mifepristone treatment 
led to an increase in ACTH and cortisol levels due 
to alterations in negative feedback in patients with 
Cushing’s disease. Another factor to be considered 
when using RU-486 is that it is difficult to assess 
patient remission because cortisol and ACTH levels International Journal of General Medicine 2009:2 212
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remain elevated even in clinically hypoadrenal 
patients. Thus, mifespristone-treated patients require 
close follow-up and frequent evaluation for clinical 
evidence of adrenal insufficiency.
Novel therapies  
for Cushing’s disease
In the past five years, renewed interest in medical therapy 
for Cushing’s disease has led to development of several 
novel therapies with potential for biochemical control and 
inhibition of pituitary tumor growth (Figure 1) .15 No clear 
efficacious candidate has yet emerged. For example, PPAR-γ 
agonists, such as rosiglitazone, initially looked promising 
but, clinical studies have been disappointing. Retinoic 
acid has been shown to effectively reduce ACTH in dogs 
with Cushing’s disease but, no human studies have been 
conducted and significant toxicity may be a limitation for 
this class of medications. The next generation somatostatin 
analog pasireotide has shown some promise in initial studies 
but drug-induced hyperglycemia may be a significant 
drawback. Studies with dopamine-agonists have also been 
completed but long term trials in humans are sparse and 
some data is inconsistent.
PPAr-γ ligands
PPAR-γ functions as a transcription factor mediating ligand-
dependent transcriptional regulation16,17 promotes adipocyte 
differentiation,18 regulates glucose metabolism,19 activates 
macrophages and monocytes,20 and facilitates angiogenesis. 
Studies of autopsy-derived normal human pituitary tissue 
revealed that immunocytochemical PPAR-γ expression was 
restricted to ACTH-secreting cells. Conversely, in pituitary 
tumor samples, including a series of ACTH-secreting tumors, 
immunocytochemical and western blot analysis revealed 
abundant PPAR-γ expression,21,22 suggesting PPAR-γ as a 
potential therapeutic target in ACTH-secreting and other 
pituitary tumors.
In  vitro  and  in  vivo  studies  with  the  PPAR-γ 
thiazolidinediones (TZDs) have supported the use of these 
drugs in inhibiting pituitary tumor growth and inhibiting 
tumor hormone synthesis and secretion.23,24 In several 
studies, PPAR-γ agonists exhibited multiple actions including 
antitumor effects, inhibition of POMC transcription, effects 
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Figure 1 Schematic summarizing the sites of action of currently available and investigational medical therapies for Cushing’s disease.International Journal of General Medicine 2009:2 213
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on ACTH receptor facilitating ACTH-negative autofeedback, 
P450c17 and 3 β-hydroxysteroid inhibition at the level of 
the adrenal gland and 11 β-hydroxysteroid 1 inhibition in 
peripheral adipose tissues.
Unfortunately, these medications have not yet demonstrated 
convincing utility in the treatment of Cushing’s disease in 
small human clinical trials. While early trials demonstrated 
decline in serum cortisol levels following initiation of 
treatment with rosiglitazone, cortisol suppression was not 
consistently observed.25 This may be due to the small number 
of enrolled patients in many of the studies or the relatively low 
doses of TZDs administered in comparison to in vivo animal 
doses. In one of the larger trials by Ambrosi and colleagues, 
14 patients were enrolled in an open-label study. Patients 
were treated with rosiglitazone 8–16 mg. Eight patients were 
nonresponders after 30–60 days. The remaining six patients 
demonstrated a significant decrease in urinary free cortisol 
but not ACTH levels. Only two of these patients continued 
to have mild clinical improvement over seven months of 
follow-up. Interestingly, on immunohistochemical analysis 
of tumor samples, of two medication responders and two 
nonresponders, similar immunoreactivity for PPAR-γ was 
observed in 50% of cells. Therefore, response to rosiglitazone 
did not necessarily correlate with immunohistochemical 
observations, raising the possibility that the TZD actions 
may not be fully mediated by PPAR-γ.26
Lack of long term benefit of rosiglitazone therapy 
was also seen in a trial by Pecori Giraldi and colleagues 
where 10 patients with Cushing’s disease were treated with 
rosiglitazone 4–16 mg daily for 1–8 months. Only three 
patients showed normalization of urinary free cortisol levels 
with a median follow-up of three months.27 In a 12-month 
study (median follow-up 6.8 months), 14 patients received 
daily rosiglitazone (up to 24 mg per day) and serum morning 
cortisol and ACTH levels were monitored.28 Although ACTH 
and cortisol levels decreased and patients improved clinically 
up to 28 weeks, patients subsequently relapsed with increased 
ACTH and cortisol levels despite maximum safe drug doses. 
In addition, magnetic resonance imaging (MRI) scans 
performed in six patients with visible tumors did not demon-
strate any change in tumor size with rosiglitazone treatment.
In addition to the lack of long-term efficacy, new 
concerns regarding rosiglitazone effects on cardiac func-
tion and bone remodeling have lowered enthusiasm for 
use of the drug in Cushing’s disease. However, the concept 
remains interesting and further studies may be warranted 
using alternative orphan receptor ligands or combination 
therapies.
retinoic acid
Retinoic acid has been shown to inhibit proliferation, invasion, 
and tumor growth in vivo and to induce differentiation and 
apoptosis in various cell types. Recent studies have also 
demonstrated that retinoic acid reduces ACTH secretion by 
inhibiting POMC gene transcription to lower corticosterone 
and inhibit in vitro and in vivo corticotroph tumor proliferation 
in murine Cushing’s disease models.29,30
In a study in 42 dogs with canine Cushing’s disease, 
retinoic acid (at a dose of 2 mg/kg/day) or ketoconazole (at a 
dose of 20 mg/kg/day), were given orally for 180 days.31 End 
points included clinical signs of hypercortisolism, plasma 
ACTH, α-melanocyte-stimulating hormone (α-MSH), 
urinary cortisol/creatinine ratio and pituitary MRI changes. 
Significant reduction was seen in plasma ACTH and α-MSH 
levels, urine cortisol/creatinine ratios and pituitary adenoma 
size at the end of the study period in the majority of retinoic 
acid-treated dogs. The authors concluded that retinoic acid 
was at least as effective as ketoconazole and offered improved 
control of the clinical and biochemical features of Cushing’s 
disease by direct corticotroph tumor actions. There were no 
recorded adverse events in the treatment group and no dogs 
developed hepatotoxicity. While these results are promising, 
the doses of retinoic acid therapy were high and studies in 
humans are necessary to verify the canine results.
Retinoic acid related toxicity may be a limiting factor 
in human Cushing’s disease. For example, in a phase II, 
open-label clinical trial in Kaposi’s sarcoma with doses 
of retinoic acid starting at 60 mg/m2 and increasing to a 
maximum dose of 140 mg/m2, serious adverse events were 
documented in five (9%) of 57 patients.32 Two patients 
developed pancreatitis associated with hypertriglyceridemia 
while receiving 140 mg/m2 of oral retinoic acid. At a dose of 
100 mg/m2, a third patient developed hypercalcemia and renal 
insufficiency and a fourth developed asthenia and shortness 
of breath. At a dose of 60 mg/m2, a fifth patient developed 
headache, requiring treatment with parenteral narcotics. Less 
severe adverse reactions included mild to moderate headache, 
dry skin, rash, alopecia, arthralgia, and diarrhea. Given this 
significant side-effect profile, further studies are needed 
before retinoic acid can be considered a safe treatment in 
human subjects with Cushing’s disease.
SOM230 (pasireotide)
Somatostatin (SRIF), a 14 aminoacid peptide, produced 
by the hypothalamus, was originally characterized as a 
potent inhibitor of GH secretion, providing the rationale for 
use of somatostatin analogs in treatment of GH-secreting International Journal of General Medicine 2009:2 214
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pituitary tumors. These agents control GH secretion in up to 
65% of acromegalic patients and have recently been shown to 
significantly reduce tumor size in up to 30% of patients.33
The currently available somatostatin analogs, octreotide 
and lanreotide are approved for treatment of acromegaly and 
carcinoid tumors. Given the observed somatostatin receptor 
expression in other pituitary tumor subtypes including 
ACTH-secreting tumors, clinical utility of somatostatin 
analogs has also been examined. An initial report published 
in 1975 reported a partial decrease in ACTH in five patients 
with Nelson’s syndrome treated with somatostatin.34 
However, other mostly single case reports, since that time, 
have reported that currently available somatostatin analogs, 
are minimally effective in controlling hormone excess in 
Cushing’s disease.
Recent emphasis has been placed on the subtypes of 
SRIF receptors. Sst5 and sst 2 are abundantly expressed in 
ACTH-secreting pituitary adenomas.35,36 While octreotide 
and lanreotide are known to have a high affinity for the sst2 
receptor type which is largely involved in the regulation of 
GH, PRL, and TSH release in human fetal anterior pituitary 
cells,37 they have only modest affinity for the sst5 subtype, 
thereby providing insight into their lack of convincing 
benefit in Cushing’s disease. Additionally, some studies have 
demonstrated down-regulation of sst2 expression secondary 
to high circulating cortisol levels, tempering enthusiasm for 
sst2 as a reliable therapeutic target.
Novel somatostatin analogs with higher sst5 binding 
affinity have now been developed. For example, SOM230 is 
a multi-receptor ligand somatostatin analog with high binding 
affinity for sst 1–3,5.38,39 As such, SOM230 has the potential 
to suppress GH, IGF-1, and ACTH secretion. Studies in 
AtT-20 murine corticotroph tumor cells demonstrated that 
sst2 and sst5 mediated inhibition of cAMP and regulation of 
ACTH secretion.40 Subsequent in vitro studies confirmed that 
human corticotroph adenomas expressed predominantly sst5 
mRNA.41 Furthermore, SOM230 treatment with 10 nmol/L 
for 72 hours inhibited pituitary tumor ACTH release and 
this SOM-230 mediated inhibition of ACTH secretion was 
not altered by glucocorticoid, suggesting that unlike the sst2 
receptor, sst5 is relatively resistant to glucocorticoid mediated 
suppression. Additionally, SOM230 administration to rats 
resulted in more marked and sustained suppression of IGF-1 
levels raising interest that this agent may offer improved 
tumor growth inhibition and/or involution.
In a recently completed phase II study, 39 adult patients 
with de novo, persistent or recurrent ACTH-dependent 
Cushing’s disease initially received pasireotide 600 µg 
subcutaneous BID for 15 days.42 Of 29 patients in the primary 
efficacy analysis, 22 (76%) showed a reduction in urine-free 
cortisol (UFC) and in five (17%) of those patients UFC 
normalized after 15 days of treatment. A significant decrease 
in serum cortisol was observed in responders verses nonre-
sponders, although no difference was observed in plasma 
ACTH. One patient, with prior type 2 diabetes mellitus, 
discontinued treatment because of hyperglycemia and of 
fourteen patients (36%) who developed hyperglycemia during 
the study, three had a history of diabetes mellitus. Thirty-six 
of 39 patients (92%) experienced one or more adverse events. 
Thirty-four (87%) of the adverse events were considered to 
be study drug-related. Gastrointestinal upset with diarrhea, 
nausea, abdominal pain, or vomiting was most common, 
occurring in 54%. Six patients (15%) developed vascular 
complaints including hypotension or flushing. None of 
these adverse events led to a patient discontinuing the study, 
although dose adjustment was needed in several patients.
This initial study appears promising although further 
long-term studies are necessary to evaluate the long-term 
efficacy and safety of pasireotide as a medical therapy for 
Cushing’s disease.
D2-agonists
Multiple dopamine receptors mediate a variety of complex 
central nervous system actions. For example, whereas 
D1-like receptors mediate excitatory functions, D2-like 
receptors (D2, D3, D4, D5) are predominantly inhibitory and 
are found in relatively high concentrations in the anterior 
and intermediate lobes of the pituitary. D2-receptor agonists 
inhibit pituitary hormone secretion, particularly, PRL- and 
proopiomelanocortin-derived hormones and drugs such as 
bromocriptine, cabergoline, pergolide, and lisuride effectively 
inhibit PRL secretion in prolactinomas.43
Corticotroph pituitary tumors also exhibit D2-receptor 
expression, up to 75% in some studies. However, earlier 
studies with the D2-agonist bromocriptine were not 
encouraging and these medications are not commonly used 
in Cushing’s disease. More recent studies, evaluating the 
efficacy of cabergoline in controlling ACTH and cortisol 
production associated with Cushing’s disease have attempted 
to characterize the mechanism of cabergoline respon-
sive vs nonresponsive cases. Absence of tumor D2-receptor 
expression correlated with lack of response to cabergoline 
and cabergoline normalized cortisol secretion in 40% of 
cases in which corticotroph tumors exhibited D2-receptor 
expression.44 Therefore, it has been proposed that dopamine 
agonists may be a therapeutic option in Cushing’s disease International Journal of General Medicine 2009:2 215
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where tumors exhibit D2-receptor expression. Clearly, 
however, determination of presence or absence of D2-receptor 
expression generally requires tissue biopsy or dopamine-
based nuclear imaging which is not very sensitive.
In a recent study, 20 patients with Cushing’s disease 
with prior unsuccessful surgical treatment were treated with 
cabergoline (initial dose of 1 mg per week with monthly 
increases to a maximum dose of 7 mg per week).45 15 patients 
(75%) demonstrated early benefit46 but sustained control of 
cortisol secretion was only observed in seven patients (35%) 
at 24 months. Furthermore, of the patients who demonstrated 
initial responsiveness to cabergoline, five had treatment 
escape and two developed drug intolerance. For the most part, 
cabergoline was well-tolerated by most patients, two devel-
oped hypotension, necessitating withdrawl of cabergoline. 
Recent studies using high-dose D2-agonist therapy in Par-
kinson’s disease patients have demonstrated cardiac valvular 
defects due to drug but in this Cushing’s study, no patients 
developed deterioration of cardiac function, although one 
patient with a history of tricuspid regurgitation did develop 
worsening valvular function.47 Of note, a majority of patients 
did experience improvement in hypertension and glucose 
intolerance, even in the absence of cortisol normalization. 
These findings renew interest in the potential use of dopa-
mine agonists in Cushing’s disease, although in many cases, 
high D2-agonist doses may be required.
A further issue is that most studies demonstrate that 
bromocriptine and cabergoline only achieve short-term 
disease remission in responsive patients and the new long 
term safety issues regarding valve disease present additional 
caveats for these medications.48
Another strategy in the medical management of Cushing’s 
disease is the use of combination dopamine agonist and 
somatostatin ligand therapy, supported by recent studies 
demonstrating coexpression of sst5 and D2 in pituitary 
corticotroph tumors.49 These reverse transcriptase-polymerase 
chain reaction studies showed that, sst5 and D2 were 
significantly co-expressed in 60% of corticotroph adenomas, 
with expression of D2 only in an additional 3% of tumors. 
Interestingly, tumors with invasive growth demonstrated 
loss of sst5 and D2 expression. These findings support the 
rationale for combination sst and D2-targeted therapy and 
early clinical studies are awaited.
11 β-hydroxysteroid dehydrogenase 
Inhibitors
11 β-hydroxysteroid dehydrogenase exists in two isoforms. 
11 β-hydroxysteroid dehydrogenasase 1 (11B-HSD1) 
catalyzes the intracellular regeneration of 11-keto forms 
(cortisone and 11-dehydrogenase) into active glucocorticoids 
(cortisol, corticosterone) in the liver, adipose tissue and brain 
whereas 11 β-hydroxysteroid dehydrogenase 2 (11B-HSD2) 
inactivates physiological glucocorticoids.50,51 Studies have 
demonstrated that 11BHSD-1 cortisol regeneration in 
visceral fat contributes significantly to the concentration 
of cortisol.52 As such, targeting the pre-receptor gluco-
corticoid activation via 11B-HSD1 inhibition provides a 
potential therapeutic target. Several drugs are in devel-
opment, including compound 544 (Merck, Whitehouse 
Station, NJ, USA), BVT.2733 (Biovitrum, Stockholm, 
Sweden), BVT-3498 (Amgen, Thousand Oaks, CA, USA) 
but, no human studies in Cushing’s disease have yet been 
conducted.
Conclusion
Thus far, medical therapy for the management of Cushing’s 
disease remains suboptimal and should be reserved for 
patients with recurrent or refractory Cushing’s, unfit 
for pituitary surgery, stereotactic radiosurgery or for 
management of preoperative severe hypercortisolism. 
Several novel therapies are under development, but fur-
ther study of these compounds is needed before they can 
be proposed for routine clinical use. Targeting of nuclear 
receptors, second generation somatostatin ligands or 
combination therapy of D2-agonists and somatostatins 
look promising in initial pre-clinical and/or early clinical 
studies. Finally, further research into patterns of receptor 
expression in corticotroph tumors, leading to increased 
understanding of the pathogenesis of these tumors may 
allow development of therapies specifically tailored to 
individual patients following analysis of a surgical tumor 
sample. Such pharmacogenomic approaches are being 
pursued in other areas of medicine.
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